Bio-economy industry press releases.

Luke Upton

Bryan Cave Leighton Paisner Advises on Sale of Stake in Harwell Science and Innovation Campus – Undertaking Critical COVID-19 Work

LONDON, 20 April 2020 – International law firm Bryan Cave Leighton Paisner LLP has advised Harwell Oxford Partners (HOP) on the sale of its 25% stake in the Harwell Science and Innovation Campus to Brookfield Asset Management.

The Campus includes the UK’s first dedicated Vaccines Manufacturing and Innovation Centre (VMIC) which is a critical part of the UK’s vaccine research infrastructure, its emergency response capability includes essential COVID-19 vaccine work.

The completion of the acquisition follows last week’s announcement by Business Secretary Alok Sharma that a UK taskforce has been established to accelerate the development of a vaccine. Notably, Sharma made specific reference to the VMIC at Harwell during Friday’s (17 April) daily press briefing.

The deal completed on 17 April 2020. U&I PLC also sold its 25% stake to Brookfield. The remaining 50% remains held by the public sector.

Angus Horner, Partner and Co-Founder of HOP, commented: “Many thanks to BCLP. All of you have been exceptionally kind, insightful and helpful. BCLP gave us important and robust legal support on myriad technically complex issues – plus proved invaluable as an additional source of good common sense and commercial points validation.”

Partners Chris de Pury (Real Estate), Adam Bogdanor and Kurt Ma (Corporate) led the BCLP team advising HOP, with Elizabeth Bradley and Andy West advising on the tax elements. Daniel Bell assisted on the corporate aspects.

BCLP also acted in 2013 on the original joint venture between HOP and Development Securities PLC (which subsequently became U+I) and on the terms of the joint venture with the public sector.

Kingsley Napley (Ian Silverblatt) provided property advice to sellers and Hogan Lovells (Nicola Evans) and Freshfields (Alex Watt) acted for U&I and Brookfield respectively.

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More